News | March 6, 2017

Deciphera Pharmaceuticals Initiates a Phase 1 Clinical Trial of DCC-3014 Waltham, MA | March 6, 2017 DCC-3014 – A Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor with Potent Macrophage Checkpoint Inhibition Activity Deciphera Pharmaceuticals, a...